by
Gus Iversen, Editor in Chief | November 11, 2025
Olympus Corporation has announced a corporate strategy aimed at expanding its presence in endoscopy-enabled care through targeted investments in technology and internal restructuring.
The Tokyo-based company said it will focus on innovation, simplification, and accountability as part of a multiyear effort to modernize its operations and position itself for long-term growth.
To support this transformation, Olympus plans to restructure its global organization, targeting approximately $155 million (24 billion yen) in run rate savings and a net workforce reduction of around 2,000 positions. The changes are expected to simplify management layers and increase agility across business units.
Ad Statistics
Times Displayed: 0
Times Visited: 0 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
The strategy includes a shift toward AI-supported endoscopy, robotics, and connected care platforms, as Olympus looks to evolve beyond hardware and into more integrated clinical solutions. According to the company, its large installed base of endoscopy systems provides a foundation to scale innovation globally, especially in areas with unmet clinical needs.
“Today marks a pivotal moment for Olympus,” said Bob White, representative executive officer, president and CEO. “We are building on our industry-leading installed base of endoscopy systems to move beyond hardware toward a future defined by intelligent, integrated care.”
The company also introduced a three-year financial plan that includes an annual revenue growth target of 5% by fiscal year 2029, 100 basis-point yearly growth starting in fiscal year 2026, and a compound annual EPS growth rate of more than 10%. Olympus said it will continue to reinvest capital in innovation, dividends, share buybacks, and acquisitions.
Several leadership changes were also announced. Keith Boettiger will take over as head of the gastrointestinal solutions division starting April 1, 2026, succeeding Frank Drewalowski, who will transition to a senior advisor role. In addition, Yasuo Takeuchi will retire from his roles as executive chairperson and ESG officer at the end of March 2026, concluding more than 40 years with the company.
